Financial Performance - The company's operating revenue for 2022 was CNY 1,418.65 million, an increase of 48.69% compared to 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 320.03 million, reflecting a 90.23% increase year-over-year[25]. - The net cash flow from operating activities increased by 273.47% to CNY 357.43 million, primarily due to increased cash receipts from sales[25]. - Total assets grew by 37.51% to CNY 2,027.09 million at the end of 2022, driven by increased fixed asset investments[25]. - Basic earnings per share for 2022 were CNY 2.95, up 73.53% from 2021[24]. - The net profit after deducting non-recurring gains and losses was CNY 303.65 million, a 108.95% increase year-over-year[23]. - The company achieved total revenue of 1,418.65 million yuan in 2022, representing a year-on-year growth of 48.69%[35]. - The net profit attributable to the parent company was 320.03 million yuan, with a year-on-year increase of 90.23%[35]. - Total assets reached 2,027.09 million yuan, up 37.51% year-on-year, while equity attributable to the parent company increased by 25.13% to 1,480.49 million yuan[35]. Dividend and Share Capital - The company plans to distribute a cash dividend of 9.00 RMB per 10 shares, totaling approximately 97,560,000 RMB, which represents 30.48% of the net profit attributable to shareholders for 2022[7]. - The company intends to increase its total share capital by 48,780,000 shares through a capital reserve transfer, resulting in a new total of 157,180,000 shares[7]. - The cash dividend policy is designed to protect the rights of minority investors and has not been adjusted during the reporting period[183]. - The company has maintained a consistent cash dividend policy that aligns with its articles of association and shareholder resolutions[187]. Research and Development - The company’s R&D expenditure accounted for 5.54% of operating revenue in 2022, consistent with the previous year[24]. - The company achieved a significant increase in R&D investment, totaling approximately ¥78.61 million, which represents a 48.76% increase compared to the previous year[71]. - The total number of newly added patents during the reporting period includes 17 invention patents and 24 utility model patents, bringing the cumulative total to 188 invention patents and 68 utility model patents[69]. - The company has established three major R&D centers, enhancing its synthetic biology research capabilities and covering the entire industrial chain from strain construction to large-scale production[36]. - The company is focusing on research and development to introduce new products in the upcoming fiscal year[159]. - The company has established a comprehensive talent development system, including various training programs to align with its long-term strategic goals[182]. Market Position and Strategy - The company has established itself as a leading producer of amino acids, with significant market share in both domestic and international markets[139]. - The company is focused on expanding its market share in the L-valine sector, where competition is intensifying[99]. - The company is actively exploring new market demands and applications for its products, particularly in emerging markets[50]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[162]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[159]. Governance and Compliance - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company adheres to legal and regulatory requirements for corporate governance, ensuring clear responsibilities among shareholders, board members, and management[151]. - There were no significant discrepancies in corporate governance compared to regulatory requirements, maintaining independence in business operations[151]. - The company has maintained compliance with shareholder meeting procedures, ensuring all resolutions were passed without objection[154]. - The company has a structured remuneration decision process for directors and senior management, with oversight from the compensation and assessment committee[167]. Operational Efficiency - The company has implemented a production model combining "sales-driven production" and "reasonable inventory," improving operational efficiency[48]. - The company has implemented standardized management practices in its sales department to enhance operational efficiency and market responsiveness[50]. - The company is focused on optimizing its production processes to reduce costs and improve the robustness of its strains for industrial applications[53]. - The company has established a comprehensive salary and performance incentive system to enhance talent attraction and employee motivation[180]. Risk Management - The company has disclosed detailed risk factors in the management discussion and analysis section of the report[4]. - The company faces risks related to technological obsolescence, as it relies on fermentation and enzyme-catalyzed production processes[88]. - The company is exposed to raw material price fluctuations, which could adversely affect its operating performance if not managed effectively[91]. - The company has a significant amount of accounts receivable, which poses a risk if not managed properly as sales expand[95]. - The company is actively monitoring changes in the international trade environment, which could impact its operations and profitability[100]. Sustainability and Innovation - The company is committed to using renewable biological resources to replace non-renewable petrochemical resources, aligning with sustainable development goals[142]. - The company has successfully implemented a biological manufacturing method that significantly reduces energy consumption and enhances product competitiveness[140]. - The management team emphasized the importance of sustainability in their future strategies, aiming for a 30% reduction in carbon emissions by 2025[163]. - The company has introduced innovative methods for the treatment and recovery of waste from L-alanine production, enhancing sustainability[64].

Financial Performance - The company's revenue for Q1 2023 reached ¥400,254,753.80, representing a year-on-year increase of 48.02%[4] - Net profit attributable to shareholders was ¥81,198,285.24, up 47.03% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥78,316,720.65, reflecting a growth of 45.97% year-on-year[4] - Basic and diluted earnings per share were both ¥0.75, marking a 47.06% increase[5] - Total operating revenue for Q1 2023 reached RMB 400,254,753.80, a 48% increase from RMB 270,406,890.76 in Q1 2022[18] - Net profit for Q1 2023 was RMB 81,188,337.13, representing a 47% increase compared to RMB 55,226,359.00 in Q1 2022[19] - The company reported a total profit of RMB 91,749,530.89 for Q1 2023, compared to RMB 64,567,911.26 in Q1 2022, an increase of 42%[19] Cash Flow and Liquidity - The net cash flow from operating activities amounted to ¥91,795,730.89, an increase of 34.41% from the previous year[4] - Cash flow from operating activities for Q1 2023 was RMB 91,795,730.89, compared to RMB 68,295,013.05 in Q1 2022, indicating a 34% increase[21] - The company achieved a total cash inflow from operating activities of RMB 427,308,791.69 in Q1 2023, compared to RMB 282,774,582.93 in Q1 2022, a 51% increase[21] - The net increase in cash and cash equivalents was $139,683,066.02, compared to $23,322,972.34 in the previous year, showing strong liquidity improvement[22] - Total cash and cash equivalents at the end of the period reached $286,656,669.32, up from $143,170,460.96 year-over-year[22] Research and Development - R&D investment totaled ¥24,726,169.10, which is 80.70% higher than the previous year, accounting for 6.18% of revenue[5] - Research and development expenses for Q1 2023 totaled RMB 24,726,169.10, significantly higher than RMB 13,683,732.27 in Q1 2022, reflecting a 81% increase[18] - The company plans to continue increasing R&D investment to support future growth[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,193,805,895.60, an increase of 8.22% from the end of the previous year[5] - The company's current assets totaled CNY 922,247,802.36, up from CNY 863,055,449.61, indicating an increase of about 6.83%[15] - Total liabilities increased to CNY 625,737,074.28 from CNY 545,440,388.40, which is an increase of about 14.69%[16] - The company's equity attributable to shareholders reached CNY 1,566,927,509.52, up from CNY 1,480,494,149.53, representing a growth of approximately 5.83%[17] Investment Activities - Net cash flow from investment activities was -$66,009,054.97, compared to -$61,460,609.14 in the previous year, indicating a decline in investment performance[22] - Cash inflow from investment activities totaled $253,204,502.81, compared to $223,432,127.42 in the previous year, reflecting growth in investment receipts[22] - The company did not absorb any new investments in the current quarter, contrasting with $6,000,000.00 received in the previous year[22] Other Financial Metrics - The return on equity (ROE) increased by 2.16 percentage points to 6.72%[5] - Cash and cash equivalents reached CNY 287,146,669.32, compared to CNY 147,463,603.30 in the previous period, reflecting a significant increase of approximately 94.93%[13] - The company's inventory decreased to CNY 124,709,065.65 from CNY 135,513,945.72, showing a decline of about 7.00%[15] - Short-term borrowings rose to CNY 193,894,995.13, compared to CNY 79,227,749.24, marking an increase of approximately 144.49%[16] - The deferred income tax liabilities increased to CNY 65,424,004.06 from CNY 54,052,854.28, reflecting an increase of approximately 21.06%[16] - The company’s retained earnings rose to CNY 802,466,156.08 from CNY 721,267,870.84, showing an increase of about 11.00%[16]

Financial Performance - The company achieved operating revenue of CNY 954,096,078.53 in 2021, representing a year-on-year increase of 95.81%[17]. - Net profit attributable to shareholders was CNY 168,235,540.04, up 38.92% compared to the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 145,322,411.47, reflecting a 50.20% increase year-on-year[17]. - Total assets reached CNY 1,474,106,341.41 at the end of 2021, a year-on-year growth of 98.43%[17]. - The company's net assets attributable to shareholders increased by 141.56% to CNY 1,183,125,104.94 compared to the beginning of the year[19]. - Basic earnings per share rose to CNY 1.70, a 13.33% increase from the previous year[18]. - The company reported a net cash flow from operating activities of CNY 95,702,545.78, down 12.66% from the previous year[17]. - The company’s amino acid product sales revenue increased significantly, with production rising from 25,043.18 tons to 48,999.67 tons, a 95.66% increase[77]. - The sales volume of amino acid products increased from 26,830.80 tons to 47,942.49 tons, representing a year-over-year growth of 78.68%[77]. Dividend Policy - The company plans to distribute a cash dividend of 5.51 RMB per 10 shares, totaling approximately 59.73 million RMB, which represents 35.50% of the net profit attributable to shareholders for 2021[4]. - The company has a cash dividend policy that mandates a minimum of 20% of distributable profits to be distributed as cash dividends if profits are positive[141]. - The company completed the 2020 profit distribution plan, distributing a cash dividend of 3.37 RMB per 10 shares, amounting to 36.40 million RMB[143]. - The cash dividend distribution plan for 2021 has been approved by the board and will be submitted for shareholder approval[143]. - The company’s board of directors has committed to maintaining a clear and transparent dividend policy in accordance with its articles of association[144]. Research and Development - The company invested 5.54% of its operating revenue in R&D, a decrease of 0.64 percentage points from the previous year[18]. - R&D expenses increased significantly to ¥52,842,997.97 from ¥30,123,885.86, representing a growth of 75.42% year-over-year[43]. - The number of R&D personnel rose to 112 from 62, with R&D staff now making up 13.83% of the total workforce, up from 9.48%[48]. - The company plans to continue increasing R&D investment, focusing on developing more bio-based new products to drive significant advancements in the field of biological manufacturing[27]. - The company has formed long-term partnerships with various research institutions to strengthen its technological innovation capabilities and talent pool[27]. Market Position and Strategy - The company has achieved a global market share of 100% for L-alanine, produced through anaerobic fermentation using renewable glucose, establishing its leading position in the industry[30]. - The company plans to continue expanding its product offerings and increasing production capacity to enhance market competitiveness[25]. - The significant growth in revenue and profit was primarily driven by increased sales volumes of valine and alanine products[25]. - The company is focused on expanding its product variety and market reach to enhance its competitive position in the bio-manufacturing industry[103]. - The marketing strategy focuses on leveraging technological leadership and exploring the potential application value of products to expand market demand[106]. Governance and Compliance - The company has not violated decision-making procedures for external guarantees[6]. - The company has confirmed that all directors attended the board meeting[5]. - The company has established a decision-making mechanism for profit distribution that includes consultation with shareholders and independent directors[145]. - The company’s governance structure complies with the Company Law and Articles of Association, ensuring the legality and validity of the meeting resolutions[114]. - The company has established specialized committees, including an audit committee and a strategic committee, to oversee various aspects of governance[133]. Environmental and Social Responsibility - The company has implemented a structured environmental management system, including policies for wastewater, solid waste, and noise control[168]. - The company reported a wastewater discharge of 8.03 tons per annum (t/a) for chemical oxygen demand (COD) and ammonia nitrogen, meeting environmental assessment standards[157]. - The company has invested up to RMB 250 million in the "Bayan Nur Huaheng Biotechnology Co., Ltd. annual production of 16,000 tons of branched-chain amino acids and their derivatives project"[162]. - The company has established emergency response plans for environmental incidents and conducts regular drills[163]. - The company actively engages in various community activities to enhance its corporate social responsibility[182]. Risks and Challenges - The company faces risks related to technological obsolescence, as failure to adapt to revolutionary new technologies could adversely affect its market competitiveness[58]. - The company’s main raw materials, including starch and glucose, have seen price increases, which could negatively impact operational performance if not managed effectively[61]. - The competitive landscape for L-Alanine is intensifying, with new capacities emerging in the industry, potentially affecting the company's business[68]. - The company has a significant accounts receivable balance, which poses a risk of liquidity tightening if not managed properly[64]. - The company benefits from tax incentives as a high-tech enterprise, but changes in tax policies could impact its financial performance[65].

Financial Performance - The company's operating revenue for Q3 2021 was ¥241,517,087.57, representing a year-on-year increase of 136.56%[4] - The net profit attributable to shareholders for Q3 2021 was ¥39,947,934.94, up 96.06% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥34,573,906.00, reflecting a 142.68% increase year-on-year[4] - Total operating revenue for Q3 2021 reached ¥621,155,770.65, a significant increase from ¥360,559,544.17 in Q3 2020, representing a growth of approximately 72.4%[17] - Net profit for Q3 2021 was ¥102,080,752.55, compared to ¥85,170,267.16 in Q3 2020, reflecting an increase of about 19.8%[18] - Operating profit for Q3 2021 was ¥111,081,485.28, up from ¥97,565,067.97 in the same quarter last year, indicating a growth of approximately 13.9%[18] Research and Development - The total R&D investment for Q3 2021 was ¥14,097,126.21, which is a 103.57% increase compared to the same period last year[5] - Research and development expenses for Q3 2021 totaled ¥33,241,754.32, compared to ¥24,765,889.86 in Q3 2020, marking an increase of about 34.1%[17] - The company plans to continue expanding its market presence and investing in R&D to support future growth[8] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥1,366,397,530.53, marking an 83.93% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2021 was ¥1,099,634,918.85, showing a 124.52% increase year-on-year[5] - The company's total current assets reached RMB 822,424,911.49, compared to RMB 261,582,018.88 in the previous year, indicating a growth of about 214.5%[14] - The total liabilities of the company were RMB 266,762,611.68, up from RMB 253,105,456.17, reflecting a rise of about 5.5%[16] - The company’s total liabilities to total assets ratio was approximately 19.5%, indicating a relatively low leverage position[16] Cash Flow - The company reported a net cash flow from operating activities of ¥80,064,950.60 for the year-to-date period, reflecting a 1.52% increase year-on-year[4] - Cash flow from operating activities for Q3 2021 was ¥80,064,950.60, slightly up from ¥78,865,335.59 in Q3 2020[21] - Cash inflow from investment activities in Q3 2021 was ¥245,194,527.19, compared to ¥1,051,366.30 in Q3 2020, showing a substantial increase[21] - Total cash outflow from investment activities for Q3 2021 was ¥705,345,715.99, compared to ¥45,814,550.41 in Q3 2020, indicating a significant rise[21] - Cash flow from financing activities in Q3 2021 amounted to ¥643,739,010.00, compared to ¥71,000,000.00 in Q3 2020, reflecting a notable increase[21] - The net cash flow from financing activities was $483,562,281.58, a significant increase compared to the previous year's negative cash flow of $19,082,469.73[22] - The total cash and cash equivalents at the end of the period reached $163,094,016.23, up from $61,159,541.22 in the same quarter last year, indicating a net increase of $103,419,622.79[22] Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose to RMB 163,701,455.07 from RMB 88,488,236.47, representing an increase of about 84.9%[14] - The company's inventory was reported at RMB 68,975,202.10, compared to RMB 47,106,045.83 in the previous year, indicating an increase of approximately 46.5%[14] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.37, an increase of 47.05% compared to the same period last year[5] - Basic earnings per share for Q3 2021 were ¥1.06, slightly higher than ¥1.05 in Q3 2020[19] Other Information - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12] - The company has adopted the new leasing standards effective January 1, 2021, but it does not involve adjustments to the opening balance of related financial statement items[22]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥379.64 million, representing a 46.88% increase compared to ¥258.46 million in the same period last year[16]. - The net profit attributable to shareholders of the listed company was approximately ¥62.13 million, a decrease of 4.11% from ¥64.80 million in the previous year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥56.17 million, down 5.47% from ¥59.41 million in the same period last year[16]. - The net cash flow from operating activities was approximately ¥110.59 million, an increase of 85.49% compared to ¥59.62 million in the previous year[16]. - The total assets at the end of the reporting period were approximately ¥1.34 billion, reflecting an 80.32% increase from ¥742.89 million at the end of the previous year[16]. - Basic earnings per share for the reporting period (1-6 months) decreased to 0.69 CNY, down 14.81% from 0.81 CNY in the same period last year[17]. - The weighted average return on equity dropped to 8.78%, a decrease of 7.38 percentage points compared to 16.16% in the previous year[17]. - The company reported a total non-operating income of 5,965,741.23 CNY, primarily from government subsidies[18]. - The company achieved a revenue of CNY 379.64 million, representing a year-on-year growth of 46.88%[46]. - The net profit attributable to shareholders was CNY 62.13 million, a decrease of 4.11% compared to the previous year, primarily due to increased operating costs and management expenses[46]. - Total assets reached CNY 1.34 billion, an increase of 80.32% from the previous year, mainly due to funds raised from the initial public offering[43]. Research and Development - R&D investment as a percentage of operating income was 5.04%, down 1.86 percentage points from 6.90% in the same period last year[17]. - The total R&D investment for the reporting period was ¥19,144,628.11, representing a 7.31% increase compared to the previous period[27]. - The proportion of R&D investment to operating income decreased by 1.86 percentage points to 5.04%[27]. - The company applied for 20 patents during the reporting period, with 12 newly granted, bringing the total granted patents to 65[26]. - The company has developed several proprietary technologies and patents related to high-yield L-alanine strains, enhancing its competitive edge in the market[22]. - The company is committed to continuous innovation and development of core technologies, including high-yield strains for L-alanine production[21]. - The company has successfully developed a continuous fermentation production technology for L-valine, which is currently at the industry-leading level[32]. - The company has made significant advancements in the production of L-Alanine, reducing production costs by approximately 50% through anaerobic fermentation technology[39]. - The company has established long-term collaborations with research institutions, enhancing its innovation capabilities and talent pool[41]. Environmental Responsibility - The company has implemented effective pollution control measures to ensure compliance with environmental regulations[65]. - The wastewater treatment plant has a processing capacity of 300 tons per day, and its operation status is good[66]. - The company reported a total wastewater discharge of 3.12 tons per year for COD and 1.58 tons per year for non-methane hydrocarbons[63]. - The company has established emergency response plans for environmental incidents and conducts regular drills[70]. - The company has confirmed that all pollution discharge meets environmental assessment standards[63]. - The company has successfully implemented a zero-emission fermentation process, contributing to environmental sustainability[25]. - The company focuses on replacing non-renewable petrochemical resources with renewable biological resources, aligning with carbon neutrality goals[25]. Shareholder Commitments and IPO - The company has fulfilled its commitments related to the initial public offering, including share lock-up agreements for major shareholders[74]. - The commitments made by the controlling shareholder and related parties are valid for 36 months from the listing date[74]. - The company will comply with the latest regulatory requirements for any share reduction actions taken after the lock-up period[82]. - The company will notify in advance before any share reduction and will implement the plan three trading days after the announcement[86]. - The company has committed to using raised funds effectively, establishing a special account for fund management to ensure dedicated use[95]. - The company has outlined a three-year shareholder dividend return plan following the initial public offering[95]. - The company promises to strictly adhere to the profit distribution policy as per the Company Law and relevant regulations after listing[96]. Financial Position and Assets - The total equity at the end of the reporting period was RMB 1,074,775,982.51[145]. - The company reported a capital increase in paid-in capital to CNY 108 million from CNY 81 million, reflecting a growth of approximately 33%[128]. - The total liabilities reached CNY 264.81 million, up from CNY 253.11 million, indicating a slight increase of about 5%[128]. - The company’s total assets at the end of the reporting period were RMB 1,074,775,982.51[145]. - The company’s financial position shows a strong equity base with total equity increasing by approximately 36.9% compared to the previous year[149]. Market and Competitive Position - The company maintains a strong customer base, including partnerships with Fortune 500 companies like BASF and Ajinomoto, ensuring timely insights into market demands[39]. - The company holds a market share close to 50% in the alanine product sector, but faces pressure for future market share growth amid potential market demand fluctuations[44]. - The company is focusing on expanding its market presence in animal nutrition and health, leveraging its advanced fermentation technologies[36]. - The company plans to invest up to 250 million RMB in a project to produce 16,000 tons of amino acids and derivatives, enhancing its product range and market competitiveness[55]. Financial Management and Cash Flow - The company reported a cash and cash equivalents balance of CNY 48,006,032.51 at the end of the period, down from CNY 52,633,952.13 at the end of the previous year[143]. - Cash inflow from financing activities amounted to CNY 624,973,400.00, a substantial increase from CNY 30,000,000.00 in the prior year[143]. - The company received CNY 19,258,605.27 in tax refunds, an increase from CNY 10,597,803.15 in the previous year[142]. - The company reported a credit impairment loss of CNY 413,046.54 for the first half of 2021, compared to a loss of CNY 1,906,934.38 in the same period of 2020, indicating an improvement[136]. Compliance and Legal Matters - The company has not reported any significant litigation or arbitration matters during the reporting period[103]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[102]. - The company has not engaged in any major related party transactions during the reporting period[104]. - The company has not reported any violations of commitments or legal regulations during the reporting period[103].